Drug Trial Radar · NCT04829604
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
72
Actual
Start
Oct 26, 2021
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Ambrx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Conditions
- HER2 Positive Metastatic Breast Cancer
Interventions
ARX788Drug
The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: 2 years
Locations
33 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
San Francisco, California
Research Site
Whittier, California
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Louisville, Kentucky
Research Site
Silver Spring, Maryland
Research Site
Boston, Massachusetts
Research Site
St Louis, Missouri
Research Site
Omaha, Nebraska
Research Site
Las Vegas, Nevada
Research Site
Camden, New Jersey
Research Site
New Hyde Park, New York
Research Site
New York, New York
Research Site
Shirley, New York
Research Site
The Bronx, New York
Research Site
Portland, Oregon
Research Site
Tigard, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Norfolk, Virginia
Research Site
Tacoma, Washington
Research Site
Frankston, Victoria, Australia
Research Site
Geelong, Victoria, Australia
Research Site
Nedlands, Western Australia, Australia
Research Site
Daegu, South Korea
Research Site
Seongnam-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.